SEARCH:   Advanced

Blood, 15 March 2007, Vol. 109, No. 6, pp. 2314-2321. Prepublished online as a Blood First Edition Paper on December 7, 2006; DOI 10.1182/blood-2005-11-025536. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2005-11-025536v1 109/6/2314    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Barbaric, D. Articles by Smith, F. O. Search for Related Content PubMed PubMed Citation Articles by Barbaric, D. Articles by Smith, F. O. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 7, 2005 Accepted October 19, 2006 Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group studies CCG-2891 and -2961 Draga Barbaric*, Todd A. Alonzo, Robert B. Gerbing, Soheil Meshinchi, Nyla A. Heerema, Dorothy R. Barnard, Beverly J. Lange, William G. Woods, Robert J. Arceci, and Franklin O. Smith Division of Hematology/Oncology/BMT, BC's Children's Hospital, Vancouver, Canada Department of Preventive Medicine, University of Southern California, Los Angeles, CA Children's Oncology Group, Arcadia, CA Fred Hutchinson Cancer Research Center, Seattle, WA Department of Pathology, Ohio State University, Columbus, OH Division of Pediatric Hematology/Oncology, IWK Health Center, Halifax, Canada Pediatric Oncology, Children's Hospital of Philadelphia, Philadelphia, PA AFLAC Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta, Atlanta, GA Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH * Corresponding author; email: dragmatt96{at}optusnet.com.au. To assess the impact of AML-M0 morphology in children, we analyzed two sequential Children's Cancer Group AML clinical trials. We compared presenting characteristics and outcomes of 82 CCG-2891 and -2961 patients with de novo, non-Down syndrome (DS) AML-M0 to 1620 with non-M0 AML, and of 10 CCG-2891 patients with DS-associated AML-M0 to 179 with DS-associated non-M0 AML. Morphology and cytogenetics were centrally reviewed. The non-DS AML-M0 children had a lower WBC (p=0.001) than their non-M0 counterparts, and a higher incidence of chromosome 5 deletions (p=0.002), non-constitutional trisomy 21 (p=0.027) and hypodiploidy (p=0.002). Outcome analyses considering all children with non-DS AML demonstrated no significant differences between M0 and non-M0 patients. Analyses restricted to intensive-timing CCG-2891 and CCG-2961 demonstrated comparable CR rates (79% and 78%) between non-DS M0 and non-M0 patients. OS from diagnosis (38±14% versus 51±3%; p=0.160) was not significantly different between the two groups. OS from end of induction (45±17% versus 63±3%; p=0.038), EFS (23±11% versus 41±3%; p=0.018), and DFS (31±14% versus 52±3%; p=0.009) were inferior in the M0 group. There was no significant outcome difference between DS-associated AML-M0 and non-M0 children. This study suggests intensively treated non-DS-associated AML-M0 children have an inferior outcome compared to children with non-M0 AML. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020